AstraZeneca rides China wave as rival GlaxoSmithKline struggles

LONDON (Reuters) - AstraZeneca is enjoying booming drug sales in China, helped by reforms to the country's regulatory system and an increased sales force, in sharp contrast to its British rival GlaxoSmithKline .